Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Dec 30;28(1):319.
doi: 10.3390/molecules28010319.

Repurposed Drugs in Gastric Cancer

Affiliations
Review

Repurposed Drugs in Gastric Cancer

Diana Araújo et al. Molecules. .

Abstract

Gastric cancer (GC) is one of the major causes of death worldwide, ranking as the fifth most incident cancer in 2020 and the fourth leading cause of cancer mortality. The majority of GC patients are in an advanced stage at the time of diagnosis, presenting a poor prognosis and outcome. Current GC treatment approaches involve endoscopic detection, gastrectomy and chemotherapy or chemoradiotherapy in an adjuvant or neoadjuvant setting. Drug development approaches demand extreme effort to identify molecular mechanisms of action of new drug candidates. Drug repurposing is based on the research of new therapeutic indications of drugs approved for other pathologies. In this review, we explore GC and the different drugs repurposed for this disease.

Keywords: anticancer drugs; gastric cancer; repurposing drugs.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Computed tomography (CT)/positron emission tomography (PET) scan of patient demonstrated moderate focal uptake along gastric body consistent with known malignancy (yellow arrow in panel (A,B)). There was also a large, mildly hypermetabolic right adnexal area with heterogenous uptake, indicating metastatic involvement (yellow circle). Kidneys (blue arrows) and bladder (orange arrow) demonstrate physiologic uptake. Reproduced from [15].
Figure 2
Figure 2
Schematic representation of repurposed drugs for gastric cancer that interfere in cell cycle.

Similar articles

Cited by

References

    1. Avital I., Nissan A., Golan T., Lawrence Y., Stojadinovic A. Cancer of the Stomach. In: DeVita V.T., Lawrence T.S., Rosenberg S.A., editors. Cancer Principles & Pratice of Oncology. Wolters Kluwer; Philadelphia, PA, USA: 2019.
    1. Turner J.R. The Gastrointestinal Tract. In: Kumar V., Abbas A., Aster J., editors. Robbins and Cotran Pathologic Basis of Disease. Elsevier Saunders; Philadelphia, PA, USA: 2015. pp. 749–819.
    1. GLOBOCAN Cancer Today—International Agency for Research on Cancer. 2020. [(accessed on 10 September 2022)]. Available online: https://gco.iarc.fr/today/
    1. Riquelme I., Saavedra K., Espinoza J., Weber H., García P., Nervi B., Garrido M., Corvalán A., Roa J., Bizama C. Molecular classification of gastric cancer: Towards a pathway driven targeted therapy. Oncotarget. 2015;6:24750–24779. doi: 10.18632/oncotarget.4990. - DOI - PMC - PubMed
    1. Ku G.Y., Ilson D.H. Cancer of the Stomach. In: Niederhuber J.E., Armitage J.O., Kastan M.B., Doroshow J.H., Tepper J.E., editors. Abeloff’s Clinical Oncology. Elsevier; Philadelphia, PA, USA: 2020. pp. 1197–1210.

MeSH terms